Increased Prevalence and Resistance of Important Pathogens Recovered from Respiratory Specimens of Cystic Fibrosis Patients During a Decade

Raidt, Lena; Idelevich, Evgeny A.; Dübbers, Angelika; Kühnl, P.; Dřevı́nek, Pavel; Peters, Georg; Kahl, Barbara C.

doi:10.1097/inf.0000000000000714

Cited by 40 publications

(23 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…aeruginosa leading to a drastic antibiotic treatments, could have favored S . maltophilia which is characterized by high level of antimicrobial resistances [59] including anti- P . aeruginosa antibiotics.…”

Section: Discussionmentioning

confidence: 99%

Strong incidence of Pseudomonas aeruginosa on bacterial rrs and ITS genetic structures of cystic fibrosis sputa

et al. 2017

View full text Add to dashboard Cite

Cystic fibrosis (CF) lungs harbor a complex community of interacting microbes, including pathogens like Pseudomonas aeruginosa. Meta-taxogenomic analysis based on V5-V6 rrs PCR products of 52 P. aeruginosa-positive (Pp) and 52 P. aeruginosa-negative (Pn) pooled DNA extracts from CF sputa suggested positive associations between P. aeruginosa and Stenotrophomonas and Prevotella, but negative ones with Haemophilus, Neisseria and Burkholderia. Internal Transcribed Spacer analyses (RISA) from individual DNA extracts identified three significant genetic structures within the CF cohorts, and indicated an impact of P. aeruginosa. RISA clusters Ip and IIIp contained CF sputa with a P. aeruginosa prevalence above 93%, and of 24.2% in cluster IIp. Clusters Ip and IIIp showed lower RISA genetic diversity and richness than IIp. Highly similar cluster IIp RISA profiles were obtained from two patients harboring isolates of a same P. aeruginosa clone, suggesting convergent evolution in the structure of their microbiota. CF patients of cluster IIp had received significantly less antibiotics than patients of clusters Ip and IIIp but harbored the most resistant P. aeruginosa strains. Patients of cluster IIIp were older than those of Ip. The effects of P. aeruginosa on the RISA structures could not be fully dissociated from the above two confounding factors but several trends in these datasets support the conclusion of a strong incidence of P. aeruginosa on the genetic structure of CF lung microbiota.

show abstract

Section: Discussionmentioning

confidence: 99%

Strong incidence of Pseudomonas aeruginosa on bacterial rrs and ITS genetic structures of cystic fibrosis sputa

et al. 2017

View full text Add to dashboard Cite

show abstract

“…There have been over 100 species of NTM identified, but two groups in particular, M. avium‐intracellulare complex (MAC) and Mycobacterium abscessus complex (MABSC), comprise the majority of NTM lung disease in cystic fibrosis (CF) patients in the United States . In the CF population, NTM is an emerging pathogen as its prevalence in the United States has climbed from 1.3% in 1984 to 14% in 2014 . CF patients are particularly prone to acquisition of NTM because of decreased mucociliary clearance, inflamed airways, and structural lung damage .…”

Section: Introductionmentioning

confidence: 99%

Household proximity to water and nontuberculous mycobacteria in children with cystic fibrosis

Bouso

Burns

Amin

et al. 2017

Pediatric Pulmonology

View full text Add to dashboard Cite

show abstract

“…24,25 Recent data from Canadian hospitals revealed that antimicrobial resistance rates continue to be higher in older age groups as compared with children and that there is considerable variability in age-specific resistance trends for different pathogens. 26 27 There is a correlation between fluoroquinolone use and the emergence of ciprofloxacin and levofloxacin resistance among Gram-negative bacilli in hospitalized children. 28 As expected, when the use of the fluoroquinolones (in particular levofloxacin) increased, the susceptibility of Gram-negative bacilli to ciprofloxacin and levofloxacin significantly decreased.…”

Section: Resistancementioning

confidence: 99%

The Use of Systemic and Topical Fluoroquinolones

Jackson¹,

Schutze²

2016

Pediatrics

142

View full text Add to dashboard Cite

Appropriate prescribing practices for fluoroquinolones, as well as all antimicrobial agents, are essential as evolving resistance patterns are considered, additional treatment indications are identified, and the toxicity profile of fluoroquinolones in children has become better defined. Earlier recommendations for systemic therapy remain; expanded uses of fluoroquinolones for the treatment of certain infections are outlined in this report. Prescribing clinicians should be aware of specific adverse reactions associated with fluoroquinolones, and their use in children should continue to be limited to the treatment of infections for which no safe and effective alternative exists or in situations in which oral fluoroquinolone treatment represents a reasonable alternative to parenteral antimicrobial therapy.

show abstract

Increased Prevalence and Resistance of Important Pathogens Recovered from Respiratory Specimens of Cystic Fibrosis Patients During a Decade

Cited by 40 publications

References 40 publications

Strong incidence of Pseudomonas aeruginosa on bacterial rrs and ITS genetic structures of cystic fibrosis sputa

Strong incidence of Pseudomonas aeruginosa on bacterial rrs and ITS genetic structures of cystic fibrosis sputa

Household proximity to water and nontuberculous mycobacteria in children with cystic fibrosis

The Use of Systemic and Topical Fluoroquinolones

Contact Info

Product

Resources

About